REGENXBIO to Present at the 6th Annual LEERINK Par

ROCKVILLE, Md., Feb. 09, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq: RGNX ), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV ^® Technology Platform, today announced that it will participate in the 6 ^th Annual LEERINK Partners Global Healthcare Conference on Wednesday, February 15, 2017 at the Lotte New York Palace in New York City.

A live webcast of REGENXBIO’s presentation is scheduled to begin at 10:30 a.m. ET and will feature a fireside chat with Kenneth T. Mills, President and Chief Executive Officer. The live webcast can be accessed in the Investors section of REGENXBIO’s website at  www.regenxbio.com . An archived replay of the webcast will be available on the same website for approximately 30 days following the presentation.

About REGENXBIO

REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. REGENXBIO’s NAV ^® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO’s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO’s NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third-party NAV Technology Platform Licensees. REGENXBIO and its licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

CONTACT: Investors Heather Savelle, 646-395-3734 heather@argotpartners.com Media Laura Bagby, 312-448-8098 lbagby@6degreespr.com